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Summary
The continuing increase in the prevalence of obesity and metabolic disorders
such as type-II diabetes and an accelerating aging population globally will
remain the major contributors to cardiovascular mortality and morbidity in the
21st century. It is well known that aging is highly associated with metabolic and
cardiovascular diseases. Growing evidence also shows that obesity and meta-
bolic diseases accelerate aging process. Studies in experimental animal models
demonstrate similarity of metabolic and cardiovascular phenotypes in metabolic
diseases and old age, e.g. insulin resistance, oxidative stress, chronic low grade
inﬂammation, cardiac hypertrophy, cardiac ﬁbrosis, and heart failure, as well as
vascular dysfunctions. Despite intensive research, the molecular mechanisms
linking metabolic stress, aging, and ultimately cardiovascular diseases are still
elusive. Although the mammalian target of rapamycin (mTOR) signalling is a
well known regulator of metabolism and lifespan in model organisms, its
central role in linking metabolic stress, aging and cardiovascular diseases is
recently emerging. In this article, we review the evidence supporting the role of
mTOR signalling as a molecular interface connecting metabolic stress, aging
and cardiovascular diseases. The therapeutic potentials of targeting mTOR sig-
nalling to protect against metabolic and age-associated cardiovascular diseases
are discussed.
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Introduction
The increasing burden of obesity and associated metabolic
disorders and an accelerating aging population globally are
predicted to become the great challenges for our society in
this century (1,2). Aging is highly associated with obesity
and metabolic disorders such as type-II diabetes as well as
cardiovascular disease which is one of the leading causes of
death (3). Evidence is emerging in recent years that obesity
and associated metabolic disorders promote cellular and
organism aging (4,5), which reduces lifespan and particu-
larly the healthy lifespan, the living period free of diseases.
There is compelling evidence showing that oxidative stress
and inﬂammation are the common mechanisms of meta-
bolic disorders associated with obesity, aging and cardio-
vascular diseases (6,7). However, the molecular pathways
that connect metabolic disorders, aging and cardiovascular
diseases are largely elusive.
Early studies provided convincing evidence for a poten-
tial role of the target of rapamycin (TOR) signalling
pathway in longevity regulation in invertebrates (8), which
has been recently extended to rodent mice (8). A role of
deregulated mammalian TOR (mTOR), also named by
some authors as ‘mechanistic TOR’ signalling, has also
been shown to be involved in obesity and associated meta-
bolic disorders (9). Only limited information is available on
the role of mTOR in metabolic and age-associated cardio-
vascular diseases. The primary emphasis of this review
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article is to discuss the emerging evidence for the role of
mTOR signalling as the molecular interface connecting
metabolic diseases, aging and cardiovascular diseases.
Regulation of mTOR signalling pathways
mTOR belongs to the phosphatidylinositol 3-kinase
(PI3K)-related kinase family with a molecular weight of
~289 kDa (10). It serves as an intracellular sensor for
energy metabolism, nutrient availability, and stresses, regu-
lating cellular and organism growth and metabolism to
adapt the environmental changes. Dys-regulation of mTOR
signalling, therefore, signiﬁcantly impacts a wide spectrum
of physiological functions and disease processes in organ-
isms (10). The detailed molecular signalling network and
regulation of mTOR signalling have been reviewed com-
prehensively in several articles (8–10). Here, we summarize
a few important biochemical features of mTOR signalling
network (Fig. 1).
mTOR complexes
mTOR, with other molecular components, forms two dis-
tinct complexes, mTOR complex 1 (mTORC1) and mTOR
complex 2 (mTORC2), in which mTOR enzymatic activity
is regulated by its unique accessory proteins raptor and
rictor, respectively. Raptor and rictor function as scaffold
proteins to recruit substrates and regulators in the respec-
tive complex.
Sensitivity to the immunosuppressant rapamycin
Rapamycin inhibits preferentially mTORC1, but chronic
treatment with rapamycin in vitro and in vivo inhibits both
mTORC1 and mTORC2 (11,12).
The upstream regulators
mTORC1 activity is regulated by multiple factors including
growth factors, stressors such as DNA damage, hypoxia,
Figure 1 Major distinct characteristics of the
two known mTOR signalling complexes,
mTORC1 and mTORC2, in composition,
rapamycin sensitivity, upstream signals,
substrates and biological functions. Adapted
from Laplante and Sabatini (10). 4EBP1,
eIF4E-binding protein 1; AMPK, AMP kinase;
Atg, autophagy related; DEPTOR, DEP
domain containing mTOR-interacting protein;
FIP200, 200 kDa FAK family
kinase-interacting protein; FOXO, forkhead
box protein O; mLST8, mammalian lethal with
sec-13 protein 8; mSin1, mammalian
stress-activated map kinase-interacting
protein 1; PPARg, peroxisome
proliferator-activated receptor-g; PRAS40,
proline-rich Akt substrate 40 kDa; protor,
protein observed with rictor; raptor,
regulatory-associated protein of mammalian
target of rapamycin; REDD1, regulated in
development and DNA damage response 1;
rictor, rapamycin-insensitive companion of
mTOR; Rom2, Rho1 GDP-GTP exchange
protein 2; SGK, serum- and
glucocorticoid-regulated kinase; SREBP,
sterol regulatory element-binding protein;
Tel2, telomere maintenance 2; TSC, the
tuberous sclerosis.
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and nutrients, while mTORC2 seems to be regulated only
by growth factors such as insulin. While the mechanisms of
mTORC1 activation are intensively investigated, the
mechanisms of mTORC2 activation are less well charac-
terized. A recent study shows that growth factors activate
mTORC2 through interaction with ribosomes in response
to PI3K stimulated by growth factors such as insulin (13).
For activation of mTORC1, the small GTPase protein
Rheb is the most proximal molecule directly activating
mTORC1 (10). Importantly, Rheb activity is negatively
regulated by the TSC1/2, the GTPase activating protein
which modulates Rheb by converting the active Rheb-GTP
into the inactive Rheb-GDP and thus reduces mTORC1
activity. Many growth factors phosphorylate and inactivate
TSC1/2 via Akt and ERK1/2 kinases, leading to activation
of Rheb-mTORC1 pathway. In contrast, energy restriction,
DNA damage or hypoxia activates TSC1/2 through acti-
vation of AMPK or REDD1, respectively, resulting in
inactivation of Rheb and inhibition of mTORC1 (Fig. 1).
There are studies indicating that AMPK inhibits mTORC1
activity through phosphorylation of raptor, resulting in
inhibition of mTORC1, which is independent of TSC1/2
(9) (Fig. 1). The nutrients amino acids, however, activate
mTORC1 speciﬁcally through Rag GTPases, which is inde-
pendent of TSC1/2. In the presence of amino acids, Rag
GTPases interact with mTORC1 and translocate the
complex from cytoplasm to lysosomal membranes where
it is activated by Rheb (10). Two research groups,
respectively, in yeast and mammalian cells, have recently
characterized that the Leucyl-tRNA synthetase exerts a
non-canonical role in amino acid-induced mTORC1 acti-
vation (14,15). In the presence of amino acids, the Leucyl-
tRNA synthetase interacts directly with Rag leading to the
formation of RagA/B-RagC/D complex in their correct
GTP/GDP-loading status (RagA/B-GTP and RagC/D-
GDP), enabling it to directly interact with raptor compo-
nent of mTORC1 and the localization of mTORC1 to
lysosomal membrane. Therefore, the Leucyl-tRNA syn-
thetase is an intracellular amino acid sensor for amino
acid-induced mTORC1 activation (Fig. 1).
The downstream effectors
mTORC1 enhances protein synthesis through S6K1 and
eIF-4E-binding protein 1 (4E-BP1), which is the best char-
acterized function of mTORC1 signalling. Upon phospho-
rylation by mTORC1, 4E-BP1 dissociates from eIF4E,
relieving its suppressing effect on mRNA translation, while
S6K1, when phosphorylated by mTORC1, promotes
mRNA translation. mTORC1 also activates the transcrip-
tion factors SREBP1 and PPARg, inducing lipogenesis in
the liver, promotes mitochondrial biogenesis and oxidative
metabolism by activating PGC1a/YY1 (reviewed in (10)).
It inhibits autophagy through phosphorylation of the
ULK1-Atg13-FIP200 complex and also through regulation
of lysosomal function (16), a central mechanism that
degrades and recycles damaged organelles in the cells,
allowing the cells to adapt to the condition of nutrient
deprivation. mTORC2 exerts its effects on metabolism,
stress responses, apoptosis, and cytoskeleton organization
through phosphorylation of many AGC kinases including
Akt, serum- and glucocorticoid-induced protein kinase
(SGK), protein kinase C-a (PKCa) and Rho1 GDP-GTP
exchange protein-2 (Rom2) (10). Since mTORC2 activates
Akt that in turn enhances mTORC1 activity through inac-
tivation of TSC1/2, mTORC2 is the upstream of mTORC1
upon stimulation by growth factors (Fig. 1).
mTOR signalling in metabolic disorders
Early studies focused much more on the role of mTORC1
signalling in regulation of cell growth and protein synthesis.
Its role in regulating metabolism has attracted much atten-
tion in recent years, together with the notion of intermittent
vs. persistent signalling to explain its differential effects. A
short-term activation of mTORC1 signalling during inter-
mittent availability of nutrients within a physiological range
is necessary for anabolic metabolism, energy storage, and
consumption, as well as normal cell/tissue development.
This is conﬁrmed by the fact that mice defective in muscle
mTORC1 activity have reduced muscle mass, decreased
PGC-1a-mediated mitochondrial oxidative metabolism,
and die early (17). However, under conditions of over-
feeding or chronically high availability of nutrients includ-
ing glucose and amino acids, a persistent activation of
mTORC1 signalling occurs (18,19) (Fig. 2). Indeed, evi-
dence demonstrates increased basal mTORC1 activity in
both genetic and diet-induced animal models of obesity and
metabolic disorders in metabolically active organs/tissues
such as liver (19), skeletal muscle (19,20), adipose tissue
(18,21), as well as vasculature (5) and heart (22,23). In
addition, in obesity and metabolic syndrome, insulin resist-
ance and hyperinsulinaemia occur. The enhanced insulin
levels further stimulate mitogenic pathways (i.e. p44/
42mapk-mTORC1) while decreasing metabolic pathways
(i.e. the Akt) resulting from hyperactive S6K1-mediated
phosphorylation of insulin receptor substrate 1 (IRS-1) at
serine residues which promotes IRS1 degradation (18)
(Fig. 2). mTORC1 has been shown to play a key role in lipid
storage by stimulating the synthesis of triglycerides in white
adipose tissue and differentiation of preadipocytes into
white adipocytes through up-regulation of PPAR-g, a factor
that up-regulates adipocyte-speciﬁc gene programme
(24,25). This is evidenced by the ﬁnding showing that
adipocyte-speciﬁc deletion of raptor in mice leads to
reduced white adipose tissue mass (26). Recent studies
also implicate a role of mTORC2 in lipogenesis through
activation of Akt-mTORC1 (27). Therefore, a chronic
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mTORC1 activation contributes to obesity by enhancing
excess fat deposition in white adipose tissue, liver and
muscle, which in turn promotes insulin resistance, leading
to reduced glucose uptake and glycogen synthesis in the
liver and muscle, and increased gluconeogenesis and
glucose release by the liver, further exacerbating hypergly-
caemia and hyperinsulinaemia that are generated by excess
nutrients (Fig. 2). Because of insulin resistance under the
condition of hyperactive mTORC1 signalling, a decreased
Akt activation unmasks activation of FOXO1 which leads
to ubiquitin ligase expression, resulting in protein catabo-
lism, so that the protein anabolic effect of mTORC1 under
the overnutrition condition does not efﬁciently occur, result-
ing in muscle wasting (28). This mechanismmay provide an
explanation for the decreased muscle mass in obesity and
aging, in which mTORC1 signalling is persistently high
(29,30). In line with these effects of mTORC1 signalling,
mice deﬁcient in the mTORC1 downstream effector S6K1
(S6K1-/-) are protected from insulin resistance and obesity
under high-fat diet (HFD) feeding, further demonstrating
the role of mTORC1-S6K1 in obesity, insulin resistance and
metabolic diseases (18) (Fig. 2).
As mentioned above, mTORC1 signalling is required for
multiple physiological functions of cells, tissues and organs:
systemic mTOR knockout in mice is embryonic lethal (31)
and systemic deﬁciency in S6K1 results in various abnor-
malities. For example, the S6K1-/- mice have reduced islets
and decreased pancreatic insulin contents, and are there-
fore hypoinsulinemic and glucose intolerant (32). This is
due to the fact that mTORC1-S6K1 signalling is necessary
for growth of pancreatic b-cells in response to glucose and
amino acids (32). On the other hand, persistent activation
of mTORC1-S6K1 signalling under the condition of over-
nutrition leads to pancreatic b-cell apoptosis through phos-
phorylation and subsequent proteosomal degradation of
IRS2 (33). Given that mTORC1-S6K1 signalling is also a
critical pathway for normal skeletal muscle growth (17),
fully inhibition of mTORC1-S6K1 signalling should not
be the goal for therapeutic purposes to treat metabolic
disorders.
mTOR signalling in aging
Evidence for a role of mTOR signalling in organism
lifespan and aging has been comprehensively demonstrated
in almost all model organisms including yeast, worms, ﬂies
and mice. Genetic inactivation or pharmacological inhibi-
tion of mTORC1 or its downstream effector kinase showed
lifespan extension in these models (8). Mice treated with
the mTORC1 inhibitor rapamycin starting at a late age
show prolonged lifespan (34,35), whereas mice treated
with rapamycin starting early in life show reduction in
age-associated learning and memory deﬁcits. Rapamycin
does not have the effects on cognition when the treatment
starts at a later age (36), suggesting that mTORC1 signal-
ling contributes to age-related decline in cognition but is
not reversible once the brain damage has already occurred.
Mice with down-regulation of insulin and insulin-like
growth factor (IGF-1) signalling show reduced mTORC1-
S6K1 activity and increased lifespan (37,38), which further
support a role for mTORC1 in the aging process (Fig. 2).
Interestingly, the effect of inhibiting mTORC1 signalling on
longevity can be mimicked by caloric restriction across
different species (8,39). Although no ﬁrm evidence exists
for the anti-aging effect of caloric restriction in humans, a
recent study has shown that caloric restriction slows aging
in rhesus monkeys (40). Moreover, it has been documented
that the Okinawa populations who consume 20% less calo-
ries compared to the average caloric consumption of the
Figure 2 mTORC1/S6K1 signalling in cardiovascular diseases related
to obesity and aging. Overnutrition leads to persistent hyperactive
mTORC1/S6K1 signalling which phosphorylates IRS-1 at serine
residues (p-S), leading to reduction in insulin signalling (mTORC2/Akt)
and decrease in insulin sensitivity, resulting in hyperglycaemia and
hyperinsulinaemia as well as metabolic imbalance via inﬂuencing
muscle growth, b-cell survival and hepatic function. The hyperactive
mTORC1/S6K1 promotes aging (directly or indirectly) and
adipogenesis, which further aggravates obesity and insulin resistance,
resulting in oxidative stress, eNOS uncoupling, inﬂammation,
pro-coagulation factor production, and decreased stem/progenitor cell
repairing capacity, and ultimately cardiovascular diseases. Fading part
of the picture represents reduced activity. Caloric restriction mimetics
inhibit mTORC1/S6K1 signalling. PAI-1, plasminogen activator
inhibitor-1; TF, tissue factor.
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Japanese population live longer and display lower inci-
dences of cancer and cardiovascular diseases in the elderly
(41). A small-scale caloric restriction study in adult humans
over 6 years also demonstrates less cardiovascular risk
factors including lower body mass index, body fat deposi-
tion, blood pressure, fasting plasma levels of glucose and
insulin, lower blood markers of inﬂammation, and beneﬁ-
cial lipid proﬁles (42), and also shows better left ventricular
diastolic function than healthy age- and sex-matched con-
trols (43). Also, patients with type-II diabetes beneﬁt from
caloric restriction and show improvement of cardiac func-
tion (44). It remains to be determined whether the beneﬁ-
cial effects of caloric restriction in humans are mediated by
inhibition of mTORC1-S6K1 signalling and whether the
anti-aging effects could be translated to lifespan extension
in healthy elderly subjects and in patients with metabolic
disorders.
It seems that the two well known downstream effectors
of mTORC1, i.e. S6K1 and 4EBP1, are involved in regu-
lation of lifespan and aging. A reduction or deﬁciency in
S6K1 activity increases lifespan in various species including
mice which are also resistant to age-related pathologies
(45). In ﬂies, loss of 4E-BP reduces lifespan extension
induced by dietary restriction, whereas overexpression of
a gain-of-function form of 4E-BP is sufﬁcient to extend
lifespan under overnutrient supply conditions (46). The
underlying molecular mechanisms are not clear. However,
substantial evidence indicates that the induction of
autophagy after inhibition of mTORC1 signalling degrades
damaged proteins or organelles, and therefore plays a
crucial role in reducing aging (47). Future work shall
conﬁrm this mechanism in higher organisms.
A recently emerging concept that remains to be con-
ﬁrmed is that mTORC1 accelerates aging by depletion
of stem/progenitor cells (Fig. 2). Inhibition of mTORC1
signalling has been shown to slow depletion of stem/
progenitor cells and improve the functions of these cells
(48). A recent study also shows that the mTORC1 signal-
ling in haematopoietic stem cells (HSC) of old mice is
higher than that of young mice and treatment of the old
mice with rapamycin improves HSC self-renewal and hae-
matopoietic function, improves immunity, and increases
lifespan (49), thereby suggesting a role for mTORC1 sig-
nalling in accelerating aging through impaired repairing
capacity of stem/progenitor cells.
Although there is compelling evidence demonstrating the
role of mTORC1-S6K1 in regulation of lifespan extension,
organism aging and metabolic stress induced by overnutri-
tion in animal models, only little information is available
about the role of mTORC1-S6K1 in cardiovascular dis-
eases associated with these conditions. In the next sections,
we will discuss the role and mechanisms of mTOR signal-
ling in pathogenesis of cardiovascular diseases under the
conditions of metabolic disorders and aging.
Cardiovascular phenotype in metabolic
disorders and aging
The cardiovascular phenotypes in metabolic diseases and
aging share many common characteristics and are accom-
panied by structural and functional changes in the heart
and blood vessels. The heart in metabolic disorders and
aging shows adaptation and maladaptation to alterations
in lipid and/or glucose metabolism, accompanied by
cardiac insulin resistance and ultimately leading to cardiac
dysfunction and heart failure (for detailed description of
metabolic changes of the heart in overnutrition, please see
(50)). The heart from patients with metabolic disorders and
in the elderly is more susceptible to myocardial ischemic
injury (51,52). Moreover, the heart in metabolic diseases
and aging exhibits cardiac hypertrophy, oxidative stress,
interstitial ﬁbrosis due to chronic deposition, and remod-
elling of extracellular matrix, leading to impaired diastolic
function and heart failure (53,54). A decreased regenerative
capacity of cardiac stem cells, possibly due to impaired cell
division and accelerated cell senescence, and an increased
cardiac myocyte apoptosis may also contribute to cardiac
dysfunction in metabolic diseases and in the elderly
(54,55). In obesity, increased perivascular adipose tissues
surrounding coronary arteries and the associated adipose
tissue inﬂammations and cardiac steatosis promote cardiac
dysfunction and coronary heart disease (56). It is well
demonstrated in the past years that obesity is associated
with chronic low-grade inﬂammation manifested by
adipose tissue pro-inﬂammatory macrophage inﬁltration
with typical crown-like structure in adipose tissues, and
increased local and systemic levels of inﬂammatory
cytokines, contributing to insulin resistance and type-II
diabetes (57). This phenotype of low-grade adipose tissue
inﬂammation is also present in aging mice (58,59). It is,
however, not clear whether the age-associated adipose
tissue inﬂammation is due to aging per se or age-associated
insulin resistance and type-II diabetes.
The vascular phenotypes in metabolic diseases and aging
also exhibit many pathological features in common. They
are associated with increased arterial wall thickening and
generalized vascular stiffness (60). At the cellular and
molecular levels, oxidative stress, vascular inﬂammation, as
well as endothelial cell and progenitor cell dysfunction
(mainly reﬂected by decreased vasoprotective endothelial
nitric oxide [NO] bioavailability) intertwine with each
other, representing the major mechanisms leading to exag-
gerated atherosclerosis in pathological conditions and aging
(6,60). In metabolic disorders and aging, the endothelial
expression of inﬂammatory adhesion molecules such as
ICAM-1 and VCAM-1 is increased (6); these participate in
the initiation and progression of atherosclerosis through
enhanced monocyte–endothelial cell interaction. Elevated
plasma concentration of sVCAM-1, sICAM-1, tissue factor
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(TF), and PAI-1, factors that are involved in inﬂammation
and thrombosis, is observed in metabolic diseases and
aging (6,61–63). Adipose tissue and endothelial cells
have been shown to be the important sources for TF
and PAI-1 production (63,64). Importantly, obesity and
aging have synergistic effects on TF and PAI-1 production
(63) (Fig. 2), which may explain the increased incidence
of thrombosis risks in patients with metabolic syndrome
and in the elderly population (65,66). Moreover, in
elderly patients and in patients with diabetes, the number
and the regenerative capacity of circulating endothelial
progenitor cells are decreased (67,68), which implicates
the impairment of cardiovascular repairing capacity after
cardiac or vascular injury under these conditions. The
underlying molecular mechanisms are, however, not clear.
Evidence suggests a critical role of oxidative stress in the
impairment of endothelial cell and progenitor cell function,
manifested by eNOS dysfunction and vascular inﬂamma-
tion (69).
Oxidative stress, eNOS uncoupling, and
vascular inﬂammation in metabolic
disorders and aging
Increased oxidative stress in metabolic disorders and aging
has been convincingly demonstrated by a wide range of
experimental and clinical studies (6,70,71). A variety of
mechanisms/enzymes that contribute to oxidative stress in
cardiovascular system in metabolic disorders and aging
have been demonstrated; these include mitochondrial dys-
function, NAD(P)H oxidase, xantine oxidase, cyclooxyge-
nase, lipoxygenase, etc. A detailed description of the role
and source of the oxidative stress has recently been the
subject of a comprehensive review article (71). Here, we
would like to focus on the role of ‘eNOS uncoupling’ as the
potential mechanism of oxidative stress in metabolic dis-
eases and aging. The endothelial NO, which is produced
via eNOS from L-arginine in the presence of the cofactor
BH4, plays a protective role against cardiovascular diseases
through multiple functions: NO causes vascular smooth
muscle relaxation, inhibits platelet aggregation and leuko-
cyte adhesion, and prevents endothelial cells from apopto-
sis and senescence (72). eNOS dysfunction or deﬁciency has
been shown to contribute to insulin resistance, accelerated
atherosclerosis, cardiac dysfunction with aging, ultimately
a signiﬁcantly shorter lifespan in mice (73–75). Although
decreased eNOS gene expression has been reported to be
responsible for endothelial dysfunction under various con-
ditions, including atherosclerosis, metabolic diseases, and
aging (72), decreased eNOS enzymatic dysfunction accom-
panied by increased eNOS gene expression is usually
observed under these conditions (76–78). The results
suggest that endothelial dysfunction in metabolic diseases
and aging is mainly attributed to eNOS enzymatic dysfunc-
tion rather than to decreased eNOS gene expression, at
least in the early stages of the diseases.
Indeed, recent studies provide increasing evidence dem-
onstrating that eNOS uncoupling is a crucial mechanism
contributing to oxidative stress in metabolic diseases and
aging as well as in atherosclerosis (78–80). Under the con-
dition of eNOS uncoupling, eNOS produces increasing
amount of O2- instead of NO (78,81) usually associated
with decreased eNOS dimer/monomer ratio (78,81).
Although the molecular mechanisms of eNOS uncoupling
remain incompletely understood, the following mecha-
nisms have been proposed:
(a) BH4 deﬁciency: the normal function of eNOS
requires homodimerization of the enzyme which is stabi-
lized by the cofactor BH4. The eNOS reductase domain
generates electron ﬂow from NADPH through FAD and
FMN ﬂavins, which are then transferred to the oxidase
domain of other monomers in which L-arginine is metabo-
lized to NO at the haem group in the active site (81). BH4
deﬁciency due to either defective synthesis or oxidative
inactivation decreases eNOS dimer/monomer ratio and the
catalytic activity of eNOS becomes uncoupled – that is –
uncoupling of NADPH oxidation and NO synthesis, with
oxygen instead of L-arginine as terminal electron acceptor,
resulting in O2- generation (81);
(b) Limited speciﬁc pool of intracellular L-arginine
bioavailability due to enhanced arginase activity (82) or
production of endogenous eNOS inhibitor asymmetric
dimethylarginine (83);
(c) The eNOS S-glutathionylation level is increased in
spontaneously hypertensive rats, a metabolic syndrome
model, as compared to normotensive animals accompanied
with impaired endothelium-dependent relaxations that
can be reversed after the S-glutathionylation of eNOS is
removed by thiol-speciﬁc reducing agents (84). Whether
S-glutathionylation of eNOS also plays a role in endothelial
dysfunction in other metabolic disease models or condi-
tions and aging remains to be explored.
mTOR signalling in eNOS uncoupling and
vascular inﬂammation in metabolic
diseases and aging
As discussed above, the physiological role of the mTOR
signalling is to support cell growth and survival. This
concept is supported by studies showing that ablation of
mTORC1 signalling is detrimental to cardiac tissue in
chronic cardiac remodelling models (85,86). However, a
persistent uncontrolled activation of mTOR signalling does
more harm than good. In the metabolic syndrome model
of spontaneously hypertensive rats, enhanced mTORC1-
S6K1 signalling has been observed in the heart, contribut-
ing to the cardiac hypertrophy (87), which is thought being
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due to decreased AMPK activity, the upstream inhibitor of
mTORC1 (88) (Fig. 1). In the left ventricles of hyperinsuli-
naemic Zucker Obese rats, mTORC1 signalling is also
elevated, which could be explained by the hyperinsulinae-
mia or other hormonal factors such as angiotensin II or
overnutrition, leading to selective activation of mTORC1
pathway (89,90). It seems that there are dynamic proﬁles of
mTORC1 signalling during the disease development. In the
overt diabetes of ZDF rats, activation of mTORC1 signal-
ling in the heart seems to be decreased to the normal level,
which could be due to the development of pancreatic
insulin deﬁciency at this stage (50). In HFD-induced obesity
and metabolic syndrome mouse model, cardiac mTORC1
activity is increased and remained elevated during ischae-
mia, which is associated with suppressed autophagy in
the heart (91). Importantly, treatment of the mice with
rapamycin signiﬁcantly enhances autophagy and reduces
ischaemic myocardial infarction size in the mice on HFD.
Similarly, genetic or pharmacological inhibition of S6K1 in
the mouse model of myocardial infarction signiﬁcantly
improves cardiac function, and reduces cardiomyocyte
apoptosis and ﬁbrotic area (92). These studies underscore
the critical role of mTORC1-S6K1 signalling in negative
cardiac remodelling induced by cardiac ischaemic injury
in the presence or absence of metabolic syndrome. Similar
to mammals, Drosophila-fed HFD develops obesity and
severe cardiac dysfunction, and genetic suppression of the
mTOR signalling pathway prevents obesity and protects
the ﬂies against HFD-induced cardiac defects (93). These
results further suggest that dys-regulation of mTOR activ-
ity mediates the deleterious effect of obesity on heart func-
tion (Fig. 2).
In the vasculature, increased mTOR signalling has also
been observed in the aortas of mice fed with HFD, which is
associated with increased vascular senescence and vascular
dysfunction and more prone to peripheral and cerebral
ischaemia, which is reduced by rapamycin treatment (5).
This study provides the ﬁrst evidence suggesting that mTOR
signalling links obesity to vascular aging (Fig. 2). In line
with the results of this study, a persistent hyperactive S6K1
activity in cultured senescent endothelial cells and in aortas
of the old rats has been observed (78). The hyperactive
S6K1 in senescent endothelial cells and aged rat aortas is
accompanied with increased O2- production derived from
eNOS uncoupling (78). The causal role of S6K1 in eNOS
uncoupling in cell senescence is demonstrated by the fact
that overexpression of a S6K1 active mutant in young
endothelial cells causes eNOS uncoupling, decreases eNOS
dimer/monomer ratio, and accelerates endothelial senes-
cence, and furthermore inhibition of mTORC1-S6K1
pathway either with rapamycin or by S6K1 silencing recou-
ples eNOS function, i.e. improves NO production and
inhibits O2- production in the senescent cells and aortas
of old rats (78). Interestingly, the naturally occurring
polyphenol resveratrol, an intensively investigated anti-
aging, anti-oxidative, and anti-inﬂammatory compound
(94,95), is able to recouple eNOS in aging through inhibi-
tion of mTORC1-S6K1 signalling (78). It is most likely
that resveratrol inhibits mTORC1-S6K1 signalling through
inhibition of mTORC2, since the hyperactive Akt, the
downstream effector kinase of mTORC2 and the upstream
signalling of mTORC1-S6K1, is observed in senescent
endothelial cells and resveratrol is able to normalize Akt
activity in the cells (78). Our ﬁnding is consistent with the
report that a hyperactive Akt plays a role in endothelial cell
senescence (96). Further studies are required to establish a
role of mTORC2 in endothelial senescence, metabolic dis-
eases, and associated cardiovascular complications, and
how resveratrol intervenes with mTORC2 activity leading
to activation of Akt-mTORC1-S6K1 pathway. Also, the
question remains whether enhanced mTOR signalling in
obesity indeed plays a causal role in obesity-associated
cardiovascular aging or vice versa.
There is considerable evidence showing that mTORC1 is
also involved in endothelial TF expression and adhesion
molecule VCAM-1 and ICAM-1 expression, which would
contribute to the vascular inﬂammatory responses and
thrombosis formation (Fig. 2). Numerous studies demon-
strate that rapamycin or silencing mTOR enhances TF
expression in endothelial cells (97,98). However, silencing
S6K1 reduces TF protein level in endothelial cells in
response to thrombin or TNF-a without affecting TF
mRNA expression. Conversely, overexpression of a consti-
tutively active S6K1 mutant enhances TF protein level even
in the mTOR-silenced cells (98). The results reveal an
opposing effect of mTOR and S6K1 on endothelial TF
expression and are best explained by the mechanisms
that the markedly enhanced TF mRNA expression under
the condition of mTORC1 inhibition is translated by
S6K1-independent pathways such as RhoA, NF-kB, and
p38mapk (98), since blockade of RhoA, NF-kB and
p38mapk either pharmacologically or genetically is able to
reduce the up-regulation of TF protein level. These ﬁndings
may have potential clinical implications. TF is highly
expressed in cells within atherosclerotic plaques (99) and
can be released into circulation after coronary intervention
(100), which favours thrombus formation. With rapamycin
(sirolimus)-eluting stents, TF expression in the vasculature
and release from vascular cells including endothelial cells,
smooth muscle cells and macrophages might be exagger-
ated because of the stimulating effect of TF expression
by the mTORC1 inhibitor. This effect of rapamycin may
increase thrombotic risk, despite its property of preventing
vascular restenosis in patients with coronary artery disease
(101), although inhibition of endothelial regeneration and
in turn endothelialization of stent surface by drug-eluting
stents may play a more prominent role in stent thrombosis
(102). Whether speciﬁc S6K1 inhibitors are able to prevent
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vascular restenosis as the mTORC1 inhibitor rapamycin,
and whether they are superior in reducing thrombotic pro-
pensity particularly in high-risk individuals such as patients
with diabetes and elderly patients, are interesting topics of
future investigations. Moreover, silencing S6K1 in endothe-
lial cells is able to prevent E-selectin expression induced by
TNF-a (103), implicating a possible role of S6K1 in regu-
lation of endothelial–leukocyte interaction. Interestingly,
high-glucose-induced VCAM-1 and ICAM-1 expression
in endothelial cells can be inhibited by resveratrol (95).
Whether this is due to inhibition of mTORC1-S6K1 sig-
nalling remains to be investigated. Further studies shall also
examine the role of mTORC1-S6K1 in TF as well as adhe-
sion molecule expression in metabolic diseases and aging
in vivo.
Conclusions
Substantial evidence demonstrates that a sustained hyper-
active mTOR signalling plays a crucial role in connecting
metabolic stress, aging, and cardiovascular diseases
through stimulation of oxidative stress and inﬂammatory
responses (integratively summarized in Fig. 2). One of the
important issues is to investigate whether targeting S6K1
directly with speciﬁc inhibitors (92) is a better approach
than targeting mTORC1 in metabolic diseases, aging and
associated cardiovascular diseases. Moreover, how much of
the beneﬁcial effects of resveratrol and Sirt1 activators are
attributable to inhibition of mTORC1-S6K1 signalling
either directly or indirectly should be investigated. Never-
theless, targeting mTOR signalling by newly developed
caloric restriction mimetics such as rapamycin analogues or
resveratrol derivatives may show less adverse effects and
hold great promise for health beneﬁts, i.e. improvement of
metabolic proﬁles in metabolic diseases, deceleration of
aging process, and improvement of cardiovascular func-
tions, ultimately leading to extension of healthy lifespan.
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